Betta Pharmaceuticals Co Ltd (300558) - Net Assets
Based on the latest financial reports, Betta Pharmaceuticals Co Ltd (300558) has net assets worth CN¥6.86 Billion CNY (≈ $1.00 Billion USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥10.69 Billion ≈ $1.56 Billion USD) and total liabilities (CN¥3.83 Billion ≈ $559.81 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Betta Pharmaceuticals Co Ltd (300558) tangible net worth to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥6.86 Billion |
| % of Total Assets | 64.21% |
| Annual Growth Rate | 41.38% |
| 5-Year Change | 42.3% |
| 10-Year Change | 245.65% |
| Growth Volatility | 61.02 |
Betta Pharmaceuticals Co Ltd - Net Assets Trend (2011–2025)
This chart illustrates how Betta Pharmaceuticals Co Ltd's net assets have evolved over time, based on quarterly financial data. See 300558 defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Betta Pharmaceuticals Co Ltd (2011–2025)
The table below shows the annual net assets of Betta Pharmaceuticals Co Ltd from 2011 to 2025. For live valuation and market cap data, see how much is Betta Pharmaceuticals Co Ltd worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥6.67 Billion ≈ $975.69 Million |
+17.68% |
| 2024-12-31 | CN¥5.67 Billion ≈ $829.13 Million |
+5.88% |
| 2023-12-31 | CN¥5.35 Billion ≈ $783.09 Million |
+7.94% |
| 2022-12-31 | CN¥4.96 Billion ≈ $725.47 Million |
+5.80% |
| 2021-12-31 | CN¥4.69 Billion ≈ $685.68 Million |
+13.06% |
| 2020-12-31 | CN¥4.14 Billion ≈ $606.47 Million |
+67.85% |
| 2019-12-31 | CN¥2.47 Billion ≈ $361.32 Million |
+10.03% |
| 2018-12-31 | CN¥2.24 Billion ≈ $328.39 Million |
+8.60% |
| 2017-12-31 | CN¥2.07 Billion ≈ $302.40 Million |
+7.13% |
| 2016-12-31 | CN¥1.93 Billion ≈ $282.28 Million |
+115.79% |
| 2015-12-31 | CN¥893.95 Million ≈ $130.81 Million |
+64.62% |
| 2014-12-31 | CN¥543.03 Million ≈ $79.46 Million |
+70.18% |
| 2013-12-31 | CN¥319.10 Million ≈ $46.69 Million |
+84.92% |
| 2012-12-31 | CN¥172.56 Million ≈ $25.25 Million |
+230.07% |
| 2011-12-31 | CN¥52.28 Million ≈ $7.65 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Betta Pharmaceuticals Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 287798183533.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥2.85 Billion | 43.14% |
| Other Components | CN¥3.75 Billion | 56.86% |
| Total Equity | CN¥6.60 Billion | 100.00% |
Betta Pharmaceuticals Co Ltd Competitors by Market Cap
The table below lists competitors of Betta Pharmaceuticals Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Towne Bank
NASDAQ:TOWN
|
$3.11 Billion |
|
Great Wall Motor Company Limited
F:GRV
|
$3.12 Billion |
|
EXOSENS PROM
PA:EXENS
|
$3.12 Billion |
|
CRRC Corporation Limited
F:C2L
|
$3.12 Billion |
|
Bank of Hawaii Corporation
NYSE:BOH
|
$3.11 Billion |
|
DOF Group ASA
OL:DOFG
|
$3.11 Billion |
|
Suzhou TZTEK Technology Co Ltd
SHG:688003
|
$3.11 Billion |
|
Zhejiang Taitan Co Ltd
SHE:003036
|
$3.11 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Betta Pharmaceuticals Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 5,573,806,060 to 6,595,157,403, a change of 1,021,351,343 (18.3%).
- Net income of 305,329,161 contributed positively to equity growth.
- Dividend payments of 150,756,175 reduced retained earnings.
- Other comprehensive income decreased equity by 585,219,736.
- Other factors increased equity by 1,451,998,093.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥305.33 Million | +4.63% |
| Dividends Paid | CN¥150.76 Million | -2.29% |
| Other Comprehensive Income | CN¥-585.22 Million | -8.87% |
| Other Changes | CN¥1.45 Billion | +22.02% |
| Total Change | CN¥- | 18.32% |
Book Value vs Market Value Analysis
This analysis compares Betta Pharmaceuticals Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.22x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 344.92x to 3.22x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | CN¥0.15 | CN¥50.54 | x |
| 2012-12-31 | CN¥0.48 | CN¥50.54 | x |
| 2013-12-31 | CN¥0.87 | CN¥50.54 | x |
| 2014-12-31 | CN¥1.49 | CN¥50.54 | x |
| 2015-12-31 | CN¥2.47 | CN¥50.54 | x |
| 2016-12-31 | CN¥5.27 | CN¥50.54 | x |
| 2017-12-31 | CN¥5.10 | CN¥50.54 | x |
| 2018-12-31 | CN¥5.61 | CN¥50.54 | x |
| 2019-12-31 | CN¥6.08 | CN¥50.54 | x |
| 2020-12-31 | CN¥10.18 | CN¥50.54 | x |
| 2021-12-31 | CN¥10.98 | CN¥50.54 | x |
| 2022-12-31 | CN¥11.67 | CN¥50.54 | x |
| 2023-12-31 | CN¥12.52 | CN¥50.54 | x |
| 2024-12-31 | CN¥13.29 | CN¥50.54 | x |
| 2025-12-31 | CN¥15.68 | CN¥50.54 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Betta Pharmaceuticals Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 4.63%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 8.46%
- • Asset Turnover: 0.34x
- • Equity Multiplier: 1.60x
- Recent ROE (4.63%) is below the historical average (22.31%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 33.58% | 27.94% | 0.29x | 4.11x | CN¥12.33 Million |
| 2012 | 61.15% | 33.58% | 1.20x | 1.52x | CN¥87.75 Million |
| 2013 | 57.68% | 37.11% | 1.17x | 1.33x | CN¥147.47 Million |
| 2014 | 50.31% | 38.23% | 1.06x | 1.24x | CN¥215.76 Million |
| 2015 | 38.87% | 37.75% | 0.80x | 1.29x | CN¥256.47 Million |
| 2016 | 19.16% | 35.63% | 0.48x | 1.13x | CN¥176.36 Million |
| 2017 | 12.56% | 25.11% | 0.37x | 1.35x | CN¥52.53 Million |
| 2018 | 7.48% | 13.63% | 0.35x | 1.57x | CN¥-56.20 Million |
| 2019 | 9.38% | 14.85% | 0.38x | 1.68x | CN¥-15.23 Million |
| 2020 | 14.64% | 32.42% | 0.36x | 1.27x | CN¥192.25 Million |
| 2021 | 8.40% | 17.06% | 0.36x | 1.38x | CN¥-73.02 Million |
| 2022 | 3.00% | 6.12% | 0.30x | 1.63x | CN¥-339.49 Million |
| 2023 | 6.63% | 14.17% | 0.27x | 1.74x | CN¥-177.08 Million |
| 2024 | 7.22% | 13.92% | 0.31x | 1.68x | CN¥-154.81 Million |
| 2025 | 4.63% | 8.46% | 0.34x | 1.60x | CN¥-354.19 Million |
Industry Comparison
This section compares Betta Pharmaceuticals Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $3,819,786,107
- Average return on equity (ROE) among peers: 5.04%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Betta Pharmaceuticals Co Ltd (300558) | CN¥6.86 Billion | 33.58% | 0.56x | $3.11 Billion |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $5.88 Billion | 7.12% | 1.83x | $612.18 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $536.15 Million | 4.62% | 0.32x | $371.95 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $0.00 | 0.00% | 0.00x | $4.52 Billion |
| Livzon Pharmaceutical Group Inc (000513) | $13.64 Billion | 12.57% | 0.51x | $2.56 Billion |
| Wedge Industrial Co Ltd (000534) | $549.14 Million | 1.31% | 0.01x | $2.22 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $893.64 Million | 25.78% | 0.79x | $12.90 Billion |
| Hainan Haiyao Co Ltd (000566) | $5.08 Billion | 1.71% | 1.08x | $734.70 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $271.26 Million | 1.07% | 1.01x | $324.84 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $1.60 Billion | -10.44% | 3.72x | $929.28 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $9.75 Billion | 6.63% | 0.12x | $3.13 Billion |
About Betta Pharmaceuticals Co Ltd
Betta Pharmaceuticals Co., Ltd. researches and develops, manufactures, and markets medicines for the treatment of cancer in China and internationally. The company offers Icotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, which is used to treat first-line treatment of locally advanced or non-small-cell lung cancer (NSCLC); Ensartinib hydrochloride, an anaplastic lymphoma… Read more